| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
VP, Chief Accounting Officer | VP, Pao And Interim Pfo
1 company
Dube Michael P is a VP, Chief Accounting Officer at Intellia Therapeutics, Inc.. Recent SEC Form 4 filings include 0 buys and 5 sells.
Estimated insider holdings value: $737K based on current market prices.
| Date | Ticker | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|
| Jan 5, 2026 | NTLA Intellia Therapeutics, Inc. | VP, Chief Accounting Officer | Sell | 2,989 | $9.21 | $27,528.69 | -5.4% | +41.9% | - | |
| Oct 1, 2025 | NTLA Intellia Therapeutics, Inc. | VP, Chief Accounting Officer | Sell | 1,871 | $17.38 | $32,517.98 | -3.3% | -51.7% | - | |
| Jul 2, 2025 | NTLA Intellia Therapeutics, Inc. | VP, Chief Accounting Officer | Sell | 2,503 | $9.95 | $24,904.85 | -4.2% | +61.0% | - | |
| Jan 3, 2025 | NTLA Intellia Therapeutics, Inc. | VP, Chief Accounting Officer | Sell | 1,372 | $12.18 | $16,710.96 | -2.9% | -43.2% | -24.1% | |
| Oct 2, 2024 | NTLA Intellia Therapeutics, Inc. | VP, Chief Accounting Officer | Sell | 2,012 | $19.01 | $38,248.12 | -4.1% | -37.1% | +10.2% |